More Clinical Lessons from the FIELD Study

@article{Fazio2008MoreCL,
  title={More Clinical Lessons from the FIELD Study},
  author={Sergio Fazio},
  journal={Cardiovascular Drugs and Therapy},
  year={2008},
  volume={23},
  pages={235-241}
}
  • S. Fazio
  • Published 22 January 2009
  • Medicine
  • Cardiovascular Drugs and Therapy
IntroductionThe Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study investigated the effect of fenofibrate treatment in 9,795 patients with type 2 diabetes.Results and discussionReduction in major coronary events (the primary endpoint) and total cardiovascular disease (CVD) events (the secondary endpoint) was similar (relative risk reduction 11%), but only significant for total CVD events (p = 0.035). The benefit of fenofibrate treatment was greater in patients with mixed… 

Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy

TLDR
Current evidence points towards the need to prescribe statins in patients with T2DM before a major decline in kidney function occurs, as well as the role of lipid-lowering drugs (mainly statins) in this field.

The Effect of Fenofibrate Treatment on Lipid Profile

Fenofibrate chemically known as 2-[4-(4-chlorobezoyl) phenoxy]-2-methylpropionic acid 1-methylethyl ester, its formula C20H21CIO4, fenofibrate is a lipophilic antihyperlipoproteinemic agent. It is a

A Comprehensive Review on the Drug: Fenofibrate

TLDR
The present review has discussed the historical development, pharmacology, analytical profile with its physicochemical properties and ongoing research scenario on this API.

How to prevent the microvascular complications of type 2 diabetes beyond glucose control

TLDR
Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade.

Diabetic cardiomyopathy: signaling defects and therapeutic approaches

TLDR
The impact of hallmark factors in diabetic cardiomyopathy, including dysregulated lipid metabolism, insulin resistance, mitochondrial dysfunction and disturbances in adipokine secretion and signaling are discussed.

Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation.

TLDR
It is hypothesized that glomerular and tubular dysfunction can be induced by increases in intracellular FA concentrations, a process that may be enabled by genetic risk variants, and warrants further investigation.

References

SHOWING 1-10 OF 44 REFERENCES

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

TLDR
Fenofibrate reduces therisk of a first MI and substantially reduces the risk of further clinical CVD events after silent MI, supporting its use in type 2 diabetes.

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

BACKGROUND Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease. In the Diabetes Atherosclerosis Intervention Study (DAIS), treatment

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

TLDR
Bezafibrate reduces the incidence of MI in patients with MS during long-term follow-up and in 575 patients with augmented features of MS (4-5 risk factors), the remarkable strengthening of cardiac mortality reduction when taking bezfibrate is noted.

Safety considerations with fibrate therapy.